Morgan Stanley raised the firm’s price target on Vertex Pharmaceuticals to $455 from $402 and keeps an Equal Weight rating on the shares. Following the close of the Alpine acquisition, the firm is adding risk-adjusted sales of Pove to its forecasts as well as refreshing its cystic fibrosis model, the analyst tells investors in a Q2 earnings preview note for the Biopharma group.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRTX:
- Vertex Pharmaceuticals announces FDA acceptance of triple combination therapy
- Verve Therapeutics appoints Nia Tatsis, Jodie Morrison to board
- Dynatrace initiated, U.S. Bancorp downgraded: Wall Street’s top analyst calls
- Vertex Pharmaceuticals initiated with a Buy at Redburn Atlantic
- QQQ ETF Update, 6/26/2024
Questions or Comments about the article? Write to editor@tipranks.com